Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

الملخص EN

Bortezomib is a first-generation proteasome inhibitor used in the treatment of multiple myeloma (MM).

A few reports have linked bortezomib exposure with the development of thrombotic microangiopathy (TMA).

We describe a case of biopsy-proven renal thrombotic microangiopathy associated with the use of bortezomib in a 51-year-old man with IgG lambda MM.

To our knowledge, this is the first biopsy-proven case.

In addition, reexposure to bortezomib 18 months later was associated with recurrence of TMA.

This supports a possible causal role of bortezomib.

The exact mechanisms remain to be elucidated.